Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2018

View Archived Issues

Plugging leaks in engineered vasculature

Activin signaling underscores resistance to platinum-based chemotherapy in lung adenocarcinoma

The exerkine apelin reverses age-associated sarcopenia

First participant enrolled in phase III study of M-001 universal flu vaccine candidate

Immunose FLU nasal influenza vaccine candidate demonstrates good safety in older adults

Phase III study of Estelle oral contraceptive meets primary efficacy endpoint

Bayer patents MKNK1 inhibitors

Researchers present new NR1I2 agonists

Medshine Discovery synthesizes WEE1hu inhibitors

Description of a phase I study evaluating locoregional immunotherapy for ovarian cancer recurrence

Positive data announced from phase II extension study of MVA-BN RSV universal vaccine

FDA approves Poteligeo for two subtypes of cutaneous T-cell lymphoma

Identification of genetic prognosticators in glioblastoma survivors by NGS

Positive topline data presented from the pivotal phase III SONICS study of Recorlev

Ambys and Takeda to pioneer first-in-class therapies for the treatment of serious liver diseases

CBT Pharmaceuticals obtains ethics approval in Australia for APOLLO-1 study

Sangamo reports positive preliminary data from Alta study of gene therapy for hemophilia A

Phase I study of EGFR CAR T-cell immunotherapy opens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.